The Zacks Analyst Blog Highlights: AbbVie, Gilead, Merck and Idenix Pharmaceuticals - Hawaii News Now - KGMB and KHNL

The Zacks Analyst Blog Highlights: AbbVie, Gilead, Merck and Idenix Pharmaceuticals

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Zacks Investment Research, Inc.

CHICAGO, June 17, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Gilead (Nasdaq:GILD-Free Report), Merck (NYSE:MRK-Free Report) and Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX-Free Report).

Zacks Investment Research, Inc., www.zacks.com.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

AbbVie Gets Priority Review from FDA for HCV Treatment

The FDA has granted priority review status to AbbVie's (NYSE:ABBV-Free Report) experimental all-oral, interferon-free therapy for the treatment of adults with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

With the new drug application (NDA) being submitted on Apr 21, AbbVie should receive a response from the FDA early in the fourth quarter.

The experimental HCV regimen has Breakthrough Therapy status which was granted by the FDA in May 2013. Breakthrough Therapy status, a new designation that became effective after Jul 9, 2012, is designed to cut short the development time of promising new treatments.

The HCV regimen has also been submitted for review in the EU where the marketing application was filed in May.

AbbVie's HCV regimen comprises ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without ribavarin. AbbVie has presented impressive data on the experimental regimen and the NDA includes data from six phase III studies. First-round approval could very well result in this new treatment hitting the market by year end.

The HCV market is attracting a lot of interest - Gilead's (Nasdaq:GILD-Free Report) Sovaldi has been bringing in billions of dollars within a few months of its approval despite concerns regarding its high price. Plus there is space in the market for additional treatments. Interest in the HCV market increased further with pharma giant Merck (NYSE:MRK-Free Report) recently announcing its intention to acquire HCV focused Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX-Free Report) for about $3.85 billion.

Several companies are looking to bring the next generation of HCV treatments to market. Gilead itself is looking to get its once-daily fixed-dose HCV cocktail treatment -- ledipasvir (NS5A inhibitor) plus Sovaldi (nucleotide analog polymerase inhibitor) -- approved in the U.S.

AbbVie is a Zacks Rank #3 (Hold) stock. Gilead, which carries a Zacks Rank #1 (Strong Buy), is a better-ranked stock.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

 

Get the full Report on ABBV - FREE

Get the full Report on GILD - FREE

Get the full Report on MRK - FREE

Get the full Report on IDIX - FREE

 

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

 

 

 

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

©2012 PR Newswire. All Rights Reserved.